Published in J Biomol Screen on July 20, 2007
Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J Immunol (2008) 1.45
Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob Agents Chemother (2010) 1.38
Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother (2013) 1.19
An in vitro study of composites of poly(L-lactide-co-ε-caprolactone), β-tricalcium phosphate and ciprofloxacin intended for local treatment of osteomyelitis. Biomatter (2013) 0.87
Cellular reporter screens for inhibitors of Burkholderia pseudomallei targets in Pseudomonas aeruginosa. Trans R Soc Trop Med Hyg (2008) 0.85
A high-throughput fluorescence polarization assay for inhibitors of gyrase B. J Biomol Screen (2011) 0.84
Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system. Antimicrob Agents Chemother (2014) 0.83
Acute exposure to silica nanoparticles enhances mortality and increases lung permeability in a mouse model of Pseudomonas aeruginosa pneumonia. Part Fibre Toxicol (2015) 0.83
Development and application of a cellular, gain-of-signal, bioluminescent reporter screen for inhibitors of type II secretion in Pseudomonas aeruginosa and Burkholderia pseudomallei. J Biomol Screen (2011) 0.81
Processing and sustained in vitro release of rifampicin containing composites to enhance the treatment of osteomyelitis. Biomatter (2013) 0.77
Fitness Cost of Fluoroquinolone Resistance in Clinical Isolates of Pseudomonas aeruginosa Differs by Type III Secretion Genotype. Front Microbiol (2016) 0.76
Discovery of bacterial fatty acid synthase type II inhibitors using a novel cellular bioluminescent reporter assay. Antimicrob Agents Chemother (2015) 0.75
DNA Targeting as a Likely Mechanism Underlying the Antibacterial Activity of Synthetic Bis-Indole Antibiotics. Antimicrob Agents Chemother (2016) 0.75
Impact of microfluidic processing on bacterial ribonucleic acid expression. Biomicrofluidics (2015) 0.75
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen (1999) 32.67
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature (2000) 32.30
Pipemidic acid: its activities against various experimental infections. Antimicrob Agents Chemother (1976) 7.92
Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid. Antimicrob Agents Chemother (1975) 5.49
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23
An improved system for gene replacement and xylE fusion analysis in Pseudomonas aeruginosa. Gene (1995) 5.18
Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother (1994) 4.87
Integration-proficient plasmids for Pseudomonas aeruginosa: site-specific integration and use for engineering of reporter and expression strains. Plasmid (2000) 4.67
A Tn7-based broad-range bacterial cloning and expression system. Nat Methods (2005) 4.66
Coordinate regulation of bacterial virulence genes by a novel adenylate cyclase-dependent signaling pathway. Dev Cell (2003) 3.72
The R-type pyocin of Pseudomonas aeruginosa is related to P2 phage, and the F-type is related to lambda phage. Mol Microbiol (2000) 2.77
Integration-proficient Pseudomonas aeruginosa vectors for isolation of single-copy chromosomal lacZ and lux gene fusions. Biotechniques (2000) 2.73
Pseudomonas aeruginosa Genome Database and PseudoCAP: facilitating community-based, continually updated, genome annotation. Nucleic Acids Res (2005) 2.61
An improved method for rapid generation of unmarked Pseudomonas aeruginosa deletion mutants. BMC Microbiol (2005) 2.53
Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem (2007) 2.44
Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1997) 2.06
Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis (2001) 2.05
Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin. J Bacteriol (2006) 1.85
Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother (2002) 1.84
Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.82
Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother (2004) 1.67
Regulation of pyocin genes in Pseudomonas aeruginosa by positive (prtN) and negative (prtR) regulatory genes. J Bacteriol (1993) 1.56
Conditional lethal amber mutations in essential Escherichia coli genes. J Bacteriol (2004) 1.35
Panel of Bacillus subtilis reporter strains indicative of various modes of action. Antimicrob Agents Chemother (2004) 1.05
Nitrogen mustard- and half-mustard-induced damage in Escherichia coli requires different DNA repair pathways. Mutat Res (2005) 0.84
Elimination of internal restriction enzyme sites from a bacterial luminescence (luxCDABE) operon. Biotechniques (1998) 0.83
Trichlormethine hydrochloride and correlation of its mutagenic and toxic effects on male germ cells in mice. Mutat Res (1992) 0.78
A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. J Microbiol Methods (2005) 6.02
A Tn7-based broad-range bacterial cloning and expression system. Nat Methods (2005) 4.66
mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa. Nat Protoc (2006) 3.19
An improved method for rapid generation of unmarked Pseudomonas aeruginosa deletion mutants. BMC Microbiol (2005) 2.53
Genetic tools for select-agent-compliant manipulation of Burkholderia pseudomallei. Appl Environ Microbiol (2007) 2.40
Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis (2008) 2.24
PBAD-based shuttle vectors for functional analysis of toxic and highly regulated genes in Pseudomonas and Burkholderia spp. and other bacteria. Appl Environ Microbiol (2008) 2.16
Two aerobic pathways for the formation of unsaturated fatty acids in Pseudomonas aeruginosa. Mol Microbiol (2006) 2.05
Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis (2004) 1.87
The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan. J Bacteriol (2002) 1.76
Versatile dual-technology system for markerless allele replacement in Burkholderia pseudomallei. Appl Environ Microbiol (2009) 1.74
Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev (2005) 1.71
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains. Antimicrob Agents Chemother (2009) 1.66
mini-Tn7 insertion in bacteria with multiple glmS-linked attTn7 sites: example Burkholderia mallei ATCC 23344. Nat Protoc (2006) 1.58
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. Antimicrob Agents Chemother (2010) 1.50
Pseudomonas aeruginosa-plant root interactions. Pathogenicity, biofilm formation, and root exudation. Plant Physiol (2003) 1.50
Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010. Emerg Infect Dis (2012) 1.48
Proteome analysis of extracellular proteins regulated by the las and rhl quorum sensing systems in Pseudomonas aeruginosa PAO1. Microbiology (2003) 1.46
Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther (2010) 1.45
Structure of the Pseudomonas aeruginosa acyl-homoserinelactone synthase LasI. Mol Microbiol (2004) 1.40
Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob Agents Chemother (2010) 1.38
Identification and characterization of TriABC-OpmH, a triclosan efflux pump of Pseudomonas aeruginosa requiring two membrane fusion proteins. J Bacteriol (2007) 1.36
Single-copy chromosomal integration systems for Francisella tularensis. Microbiology (2009) 1.34
Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS Negl Trop Dis (2009) 1.34
Method for regulated expression of single-copy efflux pump genes in a surrogate Pseudomonas aeruginosa strain: identification of the BpeEF-OprC chloramphenicol and trimethoprim efflux pump of Burkholderia pseudomallei 1026b. Antimicrob Agents Chemother (2006) 1.33
Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2005) 1.30
Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc Natl Acad Sci U S A (2011) 1.29
Substrate-dependent utilization of OprM or OpmH by the Pseudomonas aeruginosa MexJK efflux pump. Antimicrob Agents Chemother (2005) 1.29
A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists. Infect Immun (2010) 1.26
Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei. Front Microbiol (2011) 1.25
mini-Tn7 insertion in bacteria with secondary, non-glmS-linked attTn7 sites: example Proteus mirabilis HI4320. Nat Protoc (2006) 1.20
Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates. Antimicrob Agents Chemother (2010) 1.18
High-level triclosan resistance in Pseudomonas aeruginosa is solely a result of efflux. Am J Infect Control (2003) 1.18
Beta-ketoacyl acyl carrier protein reductase (FabG) activity of the fatty acid biosynthetic pathway is a determining factor of 3-oxo-homoserine lactone acyl chain lengths. Microbiology (2002) 1.16
Identification of a small-molecule entry inhibitor for filoviruses. J Virol (2011) 1.14
Solute restriction reveals an essential role for clag3-associated channels in malaria parasite nutrient acquisition. Mol Pharmacol (2012) 1.14
In vivo Bioluminescence Imaging of Burkholderia mallei Respiratory Infection and Treatment in the Mouse Model. Front Microbiol (2011) 1.14
Proteomic analysis of colony morphology variants of Burkholderia pseudomallei defines a role for the arginine deiminase system in bacterial survival. J Proteomics (2011) 1.13
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob Agents Chemother (2010) 1.10
Benchtop and microcentrifuge preparation of Pseudomonas aeruginosa competent cells. Biotechniques (2002) 1.09
Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrob Agents Chemother (2010) 1.08
In vivo Himar1 transposon mutagenesis of Burkholderia pseudomallei. Appl Environ Microbiol (2008) 1.08
Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors. J Med Chem (2010) 1.08
Expression of resistance-nodulation-cell-division efflux pumps in commonly used Burkholderia pseudomallei strains and clinical isolates from northern Australia. Trans R Soc Trop Med Hyg (2008) 1.08
Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR. Bioorg Med Chem (2010) 1.07
Two-pronged survival strategy for the major cystic fibrosis pathogen, Pseudomonas aeruginosa, lacking the capacity to degrade nitric oxide during anaerobic respiration. EMBO J (2007) 1.07
Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob Agents Chemother (2006) 1.06
New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion. J Virol (2013) 1.04
Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer. J Virol (2004) 1.02
Mini-Tn7 vectors as genetic tools for single copy gene cloning in Acinetobacter baumannii. J Microbiol Methods (2010) 1.02
In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents (2011) 1.01
Construction of mobilizable mini-Tn7 vectors for bioluminescent detection of gram-negative bacteria and single-copy promoter lux reporter analysis. Appl Environ Microbiol (2013) 1.00
Construction of a broad-host-range Tn7-based vector for single-copy P(BAD)-controlled gene expression in gram-negative bacteria. Appl Environ Microbiol (2012) 1.00
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother (2011) 0.98
Does microbicide use in consumer products promote antimicrobial resistance? A critical review and recommendations for a cohesive approach to risk assessment. Microb Drug Resist (2013) 0.96
Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli. Antimicrob Agents Chemother (2013) 0.95
Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules (2010) 0.95
Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front Cell Infect Microbiol (2012) 0.93
Molecular characterization of MexL, the transcriptional repressor of the mexJK multidrug efflux operon in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 0.92
Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses. Antimicrob Agents Chemother (2013) 0.92
Mini-Tn7 vectors as genetic tools for gene cloning at a single copy number in an industrially important and phytopathogenic bacteria, Xanthomonas spp. FEMS Microbiol Lett (2009) 0.92
Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. Antimicrob Agents Chemother (2011) 0.91
An improved method for oriT-directed cloning and functionalization of large bacterial genomic regions. Appl Environ Microbiol (2013) 0.90
Genetic characterization of pcpS, encoding the multifunctional phosphopantetheinyl transferase of Pseudomonas aeruginosa. Microbiology (2004) 0.90
Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays. Antiviral Res (2004) 0.89
Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. Antimicrob Agents Chemother (2013) 0.89
New classes of antibiotics. Curr Opin Pharmacol (2012) 0.89
Potent and broad-spectrum antibacterial activity of indole-based bisamidine antibiotics: synthesis and SAR of novel analogs of MBX 1066 and MBX 1090. Bioorg Med Chem (2013) 0.89
The Burkholderia pseudomallei Δasd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice. Infect Immun (2011) 0.89
Coumarin-based inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicase: chemical optimization, biological evaluation, and antibacterial activities. J Med Chem (2012) 0.88
Burkholderia pseudomallei known siderophores and hemin uptake are dispensable for lethal murine melioidosis. PLoS Negl Trop Dis (2012) 0.88
In vitro activity of cethromycin against Burkholderia pseudomallei and investigation of mechanism of resistance. J Antimicrob Chemother (2010) 0.88
The BpeEF-OprC efflux pump is responsible for widespread trimethoprim resistance in clinical and environmental Burkholderia pseudomallei isolates. Antimicrob Agents Chemother (2013) 0.87
Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases. Bioorg Med Chem (2009) 0.87
The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy. Antimicrob Agents Chemother (2013) 0.87
Novel bis-indole agents active against multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis (2011) 0.87
Aryl rhodanines specifically inhibit staphylococcal and enterococcal biofilm formation. Antimicrob Agents Chemother (2009) 0.86
Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus. Antiviral Res (2004) 0.86
Quorum-sensing signal synthesis by the Yersinia pestis acyl-homoserine lactone synthase YspI. J Bacteriol (2006) 0.86
Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine. Infect Immun (2013) 0.86
New insights from the 7th World Melioidosis Congress 2013. Emerg Infect Dis (2014) 0.86
Global gene expression profiles suggest an important role for nutrient acquisition in early pathogenesis in a plant model of Pseudomonas aeruginosa infection. Appl Environ Microbiol (2008) 0.85
Cellular reporter screens for inhibitors of Burkholderia pseudomallei targets in Pseudomonas aeruginosa. Trans R Soc Trop Med Hyg (2008) 0.85
MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother (2012) 0.85
Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors. Bioorg Med Chem (2011) 0.85
Pseudomonas aeruginosa thiol peroxidase protects against hydrogen peroxide toxicity and displays atypical patterns of gene regulation. J Bacteriol (2012) 0.85
Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. Antimicrob Agents Chemother (2013) 0.85
High-level pacidamycin resistance in Pseudomonas aeruginosa is mediated by an opp oligopeptide permease encoded by the opp-fabI operon. Antimicrob Agents Chemother (2013) 0.84
High-throughput screening of viral entry inhibitors using pseudotyped virus. Curr Protoc Pharmacol (2010) 0.84
Evidence of MexT-independent overexpression of MexEF-OprN multidrug efflux pump of Pseudomonas aeruginosa in presence of metabolic stress. PLoS One (2011) 0.83
Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei. Antimicrob Agents Chemother (2013) 0.83
φX216, a P2-like bacteriophage with broad Burkholderia pseudomallei and B. mallei strain infectivity. BMC Microbiol (2012) 0.83
Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system. Antimicrob Agents Chemother (2014) 0.83
Global transcriptional responses to triclosan exposure in Pseudomonas aeruginosa. Int J Antimicrob Agents (2012) 0.82
Human herpesvirus 6 U69 kinase phosphorylates the methylenecyclopropane nucleosides cyclopropavir, MBX 2168, and MBX 1616 to their monophosphates. Antimicrob Agents Chemother (2013) 0.82
Development and application of a cellular, gain-of-signal, bioluminescent reporter screen for inhibitors of type II secretion in Pseudomonas aeruginosa and Burkholderia pseudomallei. J Biomol Screen (2011) 0.81
A simple method for construction of pir+ Enterobacterial hosts for maintenance of R6K replicon plasmids. BMC Res Notes (2012) 0.81
Role of the MexXY multidrug efflux pump in moderate aminoglycoside resistance in Pseudomonas aeruginosa isolates from Pseudomonas mastitis. Microbiol Immunol (2008) 0.81
Dissecting novel virulent determinants in the Burkholderia cepacia complex. Virulence (2012) 0.80